Trial Profile
Assessing the association between single-nucleotide polymorphisms and toxicity in nivolumab-treated non-small cell lung cancer patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 May 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 02 May 2018 New trial record
- 26 Apr 2018 Results published in the British Journal of Cancer